Tokyo, Jan. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057234) titled 'A registry study of CHemotherApy-ineligible Metastatic hormone-sensitive Prostate cancer' on Jan. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Department of Urology, Sapporo Medical University School of Medicine
Condition:
Condition - metastatic hormone-sensitive prostate cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the current state of treatment and prognosis for metastatic hormone-sensitive prostate cancer (mHSPC) that does not receive chemotherapy.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old...